2016 · Tinefcon

Efficacy and Safety of Tinefcon® Tablets in Subjects with Plaque Psoriasis

Clinical Studies · Phase IV, Open-Label, Multicenter Clinical Study

In this multicenter Phase IV clinical study, 401 adults with plaque psoriasis received Tinefcon® Tablets for 12 weeks across 20 clinical sites in India. Among subjects evaluable for efficacy, the mean PASI score decreased by approximately 50% from baseline. At Week 12, 52% achieved PASI 50, 23% achieved PASI 75 and 7% achieved PASI 90. Histopathological assessment also showed reduced epidermal thickness in 66% of subjects.

Read the paper

2016 · Tinefcon

Safety and Efficacy of Tinefcon (Sphaeranthus indicus) Cream in Treatment of Plaque Psoriasis

Clinical Studies · Phase IIb, Randomized, Double-Blind, Placebo-Controlled Clinical Study

In this randomized, double-blind, placebo-controlled Phase IIb study, 86 patients with stable plaque psoriasis were evaluated over 90 days. Tinefcon® Cream produced a 69.94% reduction in target-lesion severity compared with 51.11% with placebo. In the Tinefcon® group, 70.7% achieved at least a 50% reduction in target-lesion severity. Improvements were also observed in erythema, induration, itching and pain.

Read the paper

2016 · Tinefcon

Efficacy and Safety of Two Doses of Sphaeranthus indicus Extract in the Management of Plaque Psoriasis

Clinical Studies · Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Study

This randomized, double-blind, placebo-controlled Phase II study evaluated two oral doses of Sphaeranthus indicus extract in 74 patients with moderate-to-severe plaque psoriasis over 12 weeks. In the 2.8 g/day group, 65% achieved PASI 50, 40% PASI 75 and 15% PASI 90. Improvement in Physician's Global Assessment was observed in 80% of patients receiving the higher dose.

Read the paper

2016 · Tinefcon

Sphaeranthus indicus: Traditional Wisdom to Modern Medicine—An Orally Active, Potent Cytokine Inhibitor for the Management of Inflammatory Disorders

Preclinical Research · Preclinical / Translational Mechanistic Study

Standardized Sphaeranthus indicus extract demonstrated dose-dependent inhibition of multiple pro-inflammatory cytokines and modulation of inflammatory signaling pathways, including NF-κB-related activity, across human immune cells, synovial cells and experimental models.

Read the paper

2015 · Tinefcon

A Novel Anti-Inflammatory Natural Product from Sphaeranthus indicus Inhibits Expression of VCAM1 and ICAM1, and Slows Atherosclerosis Progression Independent of Lipid Changes

Preclinical Research · Preclinical – Mechanistic / In Vivo Study

This preclinical study demonstrated inhibition of inflammatory cytokines and endothelial adhesion molecules, including VCAM-1 and ICAM-1. In experimental models, Sphaeranthus indicus also reduced aortic lesion area without altering the lipid profile, supporting an inflammation-mediated mechanism of action.

Read the paper

2012 · Tinefcon

NPS31807, a Standardized Extract from Sphaeranthus indicus, Inhibits Inflammatory, Migratory and Proliferative Activity in Keratinocytes and Immune Cells

Preclinical Research · Preclinical – Mechanism-of-Action Study

In human macrophages and epidermal keratinocytes, standardized Sphaeranthus indicus extract reduced pro-inflammatory cytokine production and modulated NF-κB and AP-1 signaling. It also inhibited pathways associated with keratinocyte proliferation and migration.

Read the paper

2011 · Tinefcon

NF-κB-Mediated Anti-Inflammatory Activity of the Sesquiterpene Lactone 7-Hydroxyfrullanolide

Preclinical Research · Preclinical – Mechanistic Study

Gene-expression and cell-based studies demonstrated that 7HF suppressed multiple inflammatory pathways, particularly NF-κB-related signaling. Further investigation showed inhibition of IKK-β phosphorylation and reduced expression of ICAM-1, VCAM-1 and E-selectin.

Read the paper

2010 · Tinefcon

7-Hydroxyfrullanolide, a Sesquiterpene Lactone, Inhibits Pro-Inflammatory Cytokine Production from Immune Cells and Is Orally Efficacious in Animal Models of Inflammation

Preclinical Research · Preclinical – In Vitro & In Vivo Study

7HF significantly and dose-dependently reduced production of the pro-inflammatory cytokines TNF-α and IL-6 in human immune cells. Oral administration also demonstrated anti-inflammatory activity across multiple experimental models of acute and chronic inflammation.

Read the paper

2025 · Eczene

Centella asiatica Tissue Culture-Derived Extracellular Vesicles: A Multifaceted Approach to Skincare Applications

Preclinical Research · In-Vitro & In-Vivo Preclinical Study

Centella asiatica-derived extracellular vesicles were evaluated across multiple skin-related biological activities. The study assessed antioxidant, melanogenesis, collagen, skin-barrier and inflammatory pathways. In a UVB-induced mouse skin-damage model, EV-containing gels were applied twice daily for seven days and evaluated for skin repair and histopathological changes. The study also reported effects on barrier-related genes including AQP3 and FLG and reductions in inflammatory markers.

bioRxiv preprint, March 2025 — not peer reviewed

Read the paper

2019 · Eczene

Validation of Botanical Treatment Efficiency for Adults and Children Suffering from Mild to Moderate Atopic Dermatitis

Clinical Studies · Multicenter, Double-Blind, Randomized, Controlled Clinical Study

108 adults and children aged 3–73 years were randomized to Kamedis Eczema Therapy Cream, its vehicle without the botanical combination, or a comparator. After four weeks, 34% of subjects receiving the test product were rated clear compared with 19% receiving vehicle. The test product demonstrated greater BSA improvement than vehicle throughout treatment, with a statistically significant difference (p=0.0369).

Journal of Drugs in Dermatology, June 2019

Read the paper

2019 · Eczene

Efficacy of Topical Botanical Treatment of Children With Mild to Moderate Atopic Dermatitis

Clinical Studies · Multicenter, Double-Blind, Randomized, Controlled Pediatric Clinical Study

39 children aged 3–18 years with mild-to-moderate AD participated. After four weeks, the botanical test product produced 61.11% SCORAD improvement and 69.4% EASI improvement. IGA showed 40% of subjects were clear and 60% clear/almost clear. The study demonstrated greater efficacy of the botanical-containing formulation compared with its vehicle.

Journal of Drugs in Dermatology, October 2019

Read the paper

2015 · Eczene

Treatment of Atopic Dermatitis with KAM-3008, a Barrier-Based, Non-Steroidal Topical Cream

Clinical Studies · Open-Label, Self-Controlled, Interventional Clinical Study

20 adults with atopic dermatitis used KAM-3008 twice daily for 21 days. Mean SCORAD improved by 18% after 14 days and 31% after 21 days. Sixteen of 20 subjects achieved at least 25% SCORAD improvement by Day 21. Significant improvements were also observed in dryness, erythema, lichenification, excoriation and oozing.

Read the paper

12 of 50